Remisyonda olan romatoid artritli hastada tedavi kararı

Ayten Yazıcı

doi:10.19161/etd.863635

TR EN

Remisyonda olan romatoid artritli hastada tedavi kararı

Öz

Romatoid artrit (RA) erişkinde en sık görülen inflamatuar artrit olup, tedavisinde remisyon veya düşük hastalık aktivitesi hedeflenmektedir. Bu nedenle öncelikle RA’da kalıcı remisyon tanımının ve süresinin kesin olarak belirlenmesi gerekmektedir. Mevcut önerilere göre en az altı aydır remisyonda olan ve sabit dozda hastalık modifiye edici ilaç (DMARD) kullanan hastalarda doz azaltılması önerilmektedir. Özellikle anti-siklik sitrüline peptid sonucu negatif, inflamatuar belirteçleri normal olan ve ultrasonografide aktif inflamasyonu olmayan hastalarda steroid kesildikten sonra biyolojik DMARD dozu veya sıklığının azaltılması, sonrasında konvansiyonel DMARD ile kombine kullanan ve halen remisyonda olanlarda biyolojik DMARD’ın kesilmesi relaps açısından daha güvenli görünmektedir. Tek başına konvansiyonel DMARD kullananlarda ise sadece doz azaltılması önerilmektedir.

Anahtar Kelimeler

References

Gerd RB, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet 2017; 389: 2338-48.
Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations fort he management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2016; 76: 960-77.
Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016; 68: 1-26.
Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016; 75 (8): 1428-37.
Smolen SF, Aletaha D, McLnnes IB. Rheumatoid arthritis. Lancet 2016; 388: 2023-38.
Aletaha D, Smolen JS. Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. Nat Rev Rheumatol 2019; doi: 10.1038/s41584-019-0279-6. (Equb ahead of print)
Dubost JJ, Pereira B, Fan A, Soubrier M. Rate of remission among rheumatoid arthritis patients being treated by rheumatologist in routine practice. Joint Bone Spine 2019; doi: 10.1016j/jbspin.2019.03.006. (Equb ahead of print)
Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskel Dis 2017; 9: 249-62.

Yilmaz-Oner S, Gazel U, Can M, Atagunduz P, Direskeneli H, Inanc N. Predictors and the optimal duration of sustained remission in rheumatoid arthritis. Clin Rheumatol 2019; doi: 10.1007/s10067-019-04654-7. (Equb ahead of print)
Lau, CS, Chia F, Dans L, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J of Rheum Dis 2019; 22: 357–75.
Lau CS, Chia F, Harrison A, et al. APLAR rheumatoid arthritis treatment recommendations. Int J of Rheum Dis 2015; 18: 685–713.
Cefle A, Keser G, Terzioğlu E ve ark. Türkiye Romatoloji Derneği romatoid artrit ulusal tedavi önerileri. Ulus Romatol Derg 2018; 10: 81-4.
Baker KF, Skelton AJ, Lendrem DW, et al. Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study. J Autoimmun 2019; doi: 10.1016/j.jaut.2019.06.009. (Equb ahead of print)
Van den Broke M, Lems WF, Allaart CF. BeSt practice: the success of early-targeted treatment in rheumatoid arthritis. Clin Exp Rheumatol 2012; 30: S35-8. 48 Ege Tıp Dergisi / Ege Journal of Medicine
Sanmarti R, Veale DJ, Martin-Mola E, et al. Reducing or maintaining the dose of subcutaneous tocilizumab in patients with rheumatoid arthritis in clinical remission: a randomized, open-label trial. Arthritis Rheumatol. 2019; doi: 10.1002/art.40905. (Equb ahead of print)
Tanaka Y. Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis. Rheumatology (Oxford) 2016;55(suppl 2):ii15-ii22.
Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015; 74: 389-95.
Haschka J, Englbrecht M, Hueber AJ, et al. Relaps rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 2016; 75: 45-51.
Mangoni AA, Okaily FA, Almoallim H, Rashidi SA, Mohammed RHA, Barbary A. Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature. BMC Rheumatol 2019; doi: 10.1186/s41927-019-0058-7. (Equb ahead of print)
Henaux S, Ruyssen-Witrand A, Cantagrel A, et al. Risk of losing remission, low disease activity or radiographic progression in case of BDMARD discontinuation or tapering in rheumatoid arthritis: systemic analysis of the literature and meta-analysis. Ann Rheum Dis 2018; 77: 515-22.
Tanaka Y, Hirata S. Is it possible to withdraw biologics from therapy in rheumatoid arthritis? Clin Ther 2013; 35: 2028-35.
Tanaka Y, Hirata S. Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis. Drugs 2014; 74 (18): 2129-39.
Schlager L, Loiskandl M, Alehata D, Radner D. Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Rheumatlogy (Oxford) 2019; doi: 10.1093/rheumatology/kez276. (Equb ahead of print).

Details

Primary Language

Turkish

Subjects

Health Care Administration

Journal Section

Case Report

Authors

Ayten Yazıcı ^*
0000-0003-2167-4509
Türkiye

Publication Date

January 20, 2021

Submission Date

April 6, 2020

Acceptance Date

August 28, 2020

Published in Issue

Year 2021

DOI

https://doi.org/10.19161/etd.863635

IZ

https://izlik.org/JA34PP56JB

Cite

RIS / Bibtex

Vancouver

1.Ayten Yazıcı. Remisyonda olan romatoid artritli hastada tedavi kararı. EJM. 2021 Jan. 1;44-8. doi:10.19161/etd.863635

Remisyonda olan romatoid artritli hastada tedavi kararı

Remisyonda olan romatoid artritli hastada tedavi kararı

Öz

Anahtar Kelimeler

Treatment decision in patient with rheumatoid arthritis in remission

Abstract

Keywords

References

Details

Primary Language

Subjects

Journal Section

Authors

Publication Date

Submission Date

Acceptance Date

Published in Issue

DOI

IZ

Cite